United Therapeutics (UTHR) CEO options exercise and large family trust gifts

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

United Therapeutics Chairperson and CEO Martine Rothblatt reported several insider transactions. On March 31, 2026, she exercised stock options to acquire 9,500 shares of Common Stock at an exercise price of $146.03 per share and sold the same 9,500 shares in multiple open-market trades at prices ranging from about $574.55 to $594.18 under a pre-arranged Rule 10b5-1 trading plan.

Following these trades, she directly holds 40,513 shares of Common Stock and stock options for 150,808 shares at an exercise price of $135.42 expiring in March 2027. In addition, family trusts associated with her made bona fide gifts totaling 1,698,384 stock options with exercise prices of $135.42 and $117.76, with no funds exchanged and no sale of shares in connection with these gifts.

Insider Trade Summary 10b5-1

Net Seller: 9,500 shares ($5,564,709)

Net Sell 27 txns

Insider ROTHBLATT MARTINE A

Role Chairperson & CEO

Sold 9,500 shs ($5.56M)

Type	Security	Shares	Price	Value
Gift	Stock Option	349,192	$0.00	--
Gift	Stock Options	349,192	$0.00	--
Gift	Stock Options	500,000	$0.00	--
Gift	Stock Options	500,000	$0.00	--
Exercise	Stock Option	9,500	$0.00	--
Exercise	Common Stock	9,500	$146.03	$1.39M
Sale	Common Stock	80	$574.5519	$46K
Sale	Common Stock	160	$577.54	$92K
Sale	Common Stock	240	$580.0804	$139K
Sale	Common Stock	503	$581.0998	$292K
Sale	Common Stock	805	$582.1936	$469K
Sale	Common Stock	1,391	$583.0801	$811K
Sale	Common Stock	980	$584.0435	$572K
Sale	Common Stock	1,161	$584.9993	$679K
Sale	Common Stock	886	$586.1355	$519K
Sale	Common Stock	467	$587.3701	$274K
Sale	Common Stock	567	$588.3763	$334K
Sale	Common Stock	600	$589.4032	$354K
Sale	Common Stock	760	$590.3559	$449K
Sale	Common Stock	700	$593.1252	$415K
Sale	Common Stock	200	$594.108	$119K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 349,192 shares (Indirect, By Trust); Stock Options — 349,192 shares (Indirect, By Trust); Stock Option — 31,000 shares (Direct); Common Stock — 50,013 shares (Direct); Common Stock — 166 shares (Indirect, by Spouse)

Footnotes (1)

This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. This transaction was executed in multiple trades at prices ranging from $574.55 to $574.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $577.39 to $577.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $579.43 to $580.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $580.52 to $581.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $581.56 to $582.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $582.58 to $583.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $583.58 to $584.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $584.58 to $585.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $585.73 to $586.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $586.875 to $587.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $587.88 to $588.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $588.89 to $589.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $589.95 to $590.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $592.63 to $593.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $594.00 to $594.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift. This stock option become exercisable in three equal annual installments beginning on the second anniversary of the grant date. The stock option was granted on March 15, 2019.

Key Figures

Options Exercised: 9,500 shares Exercise Price: $146.03/share Shares Sold: 9,500 shares +5 more

8 metrics

Options Exercised 9,500 shares Stock options exercised on March 31, 2026 at $146.03

Exercise Price $146.03/share Stock option exercise into 9,500 common shares

Shares Sold 9,500 shares Open-market sales on March 31, 2026 under 10b5-1 plan

Sale Price Range $574.55–$594.18 Weighted-average price ranges from multiple sale transactions

Direct Shares Held 40,513 shares Common Stock directly owned after March 31, 2026 trades

Remaining Options 150,808 shares Underlying shares for options at $135.42 expiring March 15, 2027

Gifted Stock Options 1,698,384 options Bona fide gifts by family trusts at $135.42 and $117.76

10b5-1 Plan Cap 1,734,410 options Maximum options to be exercised under plan expiring December 31, 2026

Key Terms

Rule 10b5-1 trading plan, bona fide gift, stock option, weighted average price, +2 more

6 terms

Rule 10b5-1 trading plan regulatory

"pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

bona fide gift financial

"transaction_code_description": "Bona fide gift""

stock option financial

"This stock option was gifted from a trust beneficially owned by the Reporting Person"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

weighted average price financial

"The price reported above reflects the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

family trusts financial

"Shares held in family trusts as to which the Reporting Person shares investment power"

exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 04:34 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

MARYLAND

20910

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairperson & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/31/2026		M⁽¹⁾		9,500	A	$146.03	50,013	D
Common Stock	03/31/2026		S⁽¹⁾		80	D	$574.5519⁽²⁾	49,933	D
Common Stock	03/31/2026		S⁽¹⁾		160	D	$577.54⁽³⁾	49,773	D
Common Stock	03/31/2026		S⁽¹⁾		240	D	$580.0804⁽⁴⁾	49,533	D
Common Stock	03/31/2026		S⁽¹⁾		503	D	$581.0998⁽⁵⁾	49,030	D
Common Stock	03/31/2026		S⁽¹⁾		805	D	$582.1936⁽⁶⁾	48,225	D
Common Stock	03/31/2026		S⁽¹⁾		1,391	D	$583.0801⁽⁷⁾	46,834	D
Common Stock	03/31/2026		S⁽¹⁾		980	D	$584.0435⁽⁸⁾	45,854	D
Common Stock	03/31/2026		S⁽¹⁾		1,161	D	$584.9993⁽⁹⁾	44,693	D
Common Stock	03/31/2026		S⁽¹⁾		886	D	$586.1355⁽¹⁰⁾	43,807	D
Common Stock	03/31/2026		S⁽¹⁾		467	D	$587.3701⁽¹¹⁾	43,340	D
Common Stock	03/31/2026		S⁽¹⁾		567	D	$588.3763⁽¹²⁾	42,773	D
Common Stock	03/31/2026		S⁽¹⁾		600	D	$589.4032⁽¹³⁾	42,173	D
Common Stock	03/31/2026		S⁽¹⁾		760	D	$590.3559⁽¹⁴⁾	41,413	D
Common Stock	03/31/2026		S⁽¹⁾		700	D	$593.1252⁽¹⁵⁾	40,713	D
Common Stock	03/31/2026		S⁽¹⁾		200	D	$594.108⁽¹⁶⁾	40,513	D
Common Stock								166	I	by Spouse
Common Stock								324,518	I	by Trust⁽¹⁷⁾
Common Stock								258,117	I	by Trust⁽¹⁸⁾
Common Stock								45,596	I	by Trust⁽¹⁹⁾
Common Stock								10,962	I	by Trust⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$146.03	03/31/2026		M⁽¹⁾			9,500	03/15/2020	03/15/2027	Common Stock	9,500	$0.00	31,000	D
Stock Option	$135.42	04/01/2026		G⁽²⁰⁾			349,192	03/15/2023	03/15/2027	Common Stock	349,192	$0.00	349,192	I	By Trust⁽²⁰⁾
Stock Options	$135.42	04/01/2026		G⁽²⁰⁾		349,192		03/15/2023	03/15/2027	Common Stock	349,192	$0.00	349,192	I	By Trust⁽²⁰⁾
Common Stock	$135.42							03/15/2023	03/15/2027	Common Stock	150,808		150,808	D
Stock Options	$117.76	04/01/2026		G⁽²⁰⁾			500,000	⁽²¹⁾	03/15/2027	Common Stock	500,000	$0.00	0.00	I	By Trusts⁽²⁰⁾
Stock Options	$117.76	04/01/2026		G⁽²⁰⁾		500,000		⁽²¹⁾	03/15/2027	Common Stock	500,000	$0.00	500,000	I	By Trusts⁽²⁰⁾

Explanation of Responses:

1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

2. This transaction was executed in multiple trades at prices ranging from $574.55 to $574.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $577.39 to $577.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $579.43 to $580.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $580.52 to $581.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $581.56 to $582.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $582.58 to $583.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $583.58 to $584.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $584.58 to $585.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $585.73 to $586.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $586.875 to $587.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. This transaction was executed in multiple trades at prices ranging from $587.88 to $588.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

13. This transaction was executed in multiple trades at prices ranging from $588.89 to $589.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

14. This transaction was executed in multiple trades at prices ranging from $589.95 to $590.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

15. This transaction was executed in multiple trades at prices ranging from $592.63 to $593.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

16. This transaction was executed in multiple trades at prices ranging from $594.00 to $594.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

17. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

18. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

19. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

20. This stock option was gifted from a trust beneficially owned by the Reporting Person to a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. The gift was made pursuant to an agreement entered into on November 21, 2025 which provided that the number of stock options to be gifted would be based on set formula using a valuation to be conducted on April 1, 2026. The actual number of stock options to be gifted was determined on April 1, 2026 and the gift occurred on the same date. No funds were exchanged, and no sale of shares occurred in the gift.

21. This stock option become exercisable in three equal annual installments beginning on the second anniversary of the grant date. The stock option was granted on March 15, 2019.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did United Therapeutics (UTHR) CEO Martine Rothblatt report?

Martine Rothblatt reported exercising 9,500 stock options at $146.03 per share and selling 9,500 common shares in multiple open-market trades around $574.55–$594.18 under a pre-arranged Rule 10b5-1 trading plan.

How many United Therapeutics (UTHR) shares does the CEO hold after these Form 4 transactions?

After the reported trades, Martine Rothblatt directly holds 40,513 shares of United Therapeutics common stock and stock options covering 150,808 shares at a $135.42 exercise price expiring in March 2027.

Were the United Therapeutics (UTHR) CEO’s stock sales part of a Rule 10b5-1 plan?

Yes. The exercise of options and sale of 9,500 resulting common shares were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, with specified limits and an end date of December 31, 2026.

What gifts of United Therapeutics (UTHR) stock options were reported by family trusts?

Family trusts associated with Martine Rothblatt reported bona fide gifts totaling 1,698,384 stock options with exercise prices of $135.42 and $117.76. Footnotes state no funds were exchanged and no sale of shares occurred in connection with these gifts.

What option position remains for the United Therapeutics (UTHR) CEO after the Form 4 filing?

The filing shows remaining stock options relating to 150,808 underlying United Therapeutics common shares, with a $135.42 exercise price and a March 15, 2027 expiration date, held directly by Martine Rothblatt.